Evaluation of a Particulate Breast Cancer Vaccine Delivered via Skin

Chablani, Lipika; Tawde, Suprita A.; Akalkotkar, Archana; D’Souza, Martin J.

doi:10.1208/s12248-018-0285-7

Cited by 31 publications

(25 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Therapy Protein/peptide drug MNs type MNs material Ref. Cancer vaccine OVA Dissolving MNs PMVE/MA 118 OVA and resiquimod (R848) Dissolving MNs Pluronic F127/PEG 181 Human melanoma antigens (Trp2) and adjuvant (CpG) Coated MNs PLLA 182 Microparticulate ovarian cancer vaccine AdminPen™ (Hollow MNs) Stainless steel 183 Whole cell lysate of B16F10 cancer cells, GM-CSF Dissolving MNs HA 184 Murine breast cancer whole cell lysate Solid MNs Metal 185 S-91 melanoma cancer cells vaccine antigen Solid MNs Dermaroller 186 HPV E743–63 synthetic long peptide Hollow MNs Silica capillaries 63 Gene therapy Octaarginine/BRAF siRNA Coated MNs Stainless steel 187 Plasmid OVA and poly(I:C) Dissolving MNs A cationic polypeptide and PEG 188 Checkpoint inhibitors aPD-1 Dissolving MNs HA 189 aPD-1 Hollow MNs PVP/PVA 190 aCTLA-4 Dissolving MNs PVP 191 aPD-1 and 1-methyl- d , l -tryptophan Dissolving MNs HA 192 aCTLA-4 and zinc phthalocyanine …”

Section: Application Of Mns-mediated Protein and Peptide Deliverymentioning

confidence: 99%

Recent advances in microneedles-mediated transdermal delivery of protein and peptide drugs

Liu

Chen

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Proteins and peptides have become a significant therapeutic modality for various diseases because of their high potency and specificity. However, the inherent properties of these drugs, such as large molecular weight, poor stability, and conformational flexibility, make them difficult to be formulated and delivered. Injection is the primary route for clinical administration of protein and peptide drugs, which usually leads to poor patient's compliance. As a portable, minimally invasive device, microneedles (MNs) can overcome the skin barrier and generate reversible microchannels for effective macromolecule permeation. In this review, we highlighted the recent advances in MNs-mediated transdermal delivery of protein and peptide drugs. Emphasis was given to the latest development in representative MNs design and fabrication. We also summarize the current application status of MNs-mediated transdermal protein and peptide delivery, especially in the field of infectious disease, diabetes, cancer, and other disease therapy. Finally, the current status of clinical translation and a perspective on future development are also provided.

show abstract

Section: Application Of Mns-mediated Protein and Peptide Deliverymentioning

confidence: 99%

Recent advances in microneedles-mediated transdermal delivery of protein and peptide drugs

Liu

Chen

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

show abstract

“…The minimally invasive and cost-effective features of MNs have aroused their rapid development and extensive exploration in cancer vaccine delivery recently ( Table 2 ). Various types of MNs have been investigated for cancer vaccine delivery, as depicted in Figure 4 , including solid MNs ( Bhowmik et al, 2011 ; Chablani et al, 2019 ), dissolving MNs ( Zaric et al, 2013 ; Gala et al, 2018 ; Kim et al, 2018 ; Cole et al, 2019 ; Kim et al, 2019 ), coated MNs ( Zeng et al, 2017 ; Duong et al, 2018 ) and hollow MNs ( van der Maaden et al, 2018 ; Niu et al, 2019 ). Novel design to utilize parallel circular blades with MN on edge as electrodes was also studied for their ability to deliver siRNA targeting PD-L1 alone, or combined with anti-PD-1 antibody and immunoadjuvant CpG 2395 ( Yang et al, 2021 ).…”

Section: Controlled-release Drug Delivery Systemsmentioning

confidence: 99%

Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines

et al. 2021

View full text Add to dashboard Cite

Cancer vaccines represent among the most promising strategies in the battle against cancers. However, the clinical efficacy of current cancer vaccines is largely limited by the lack of optimized delivery systems to generate strong and persistent antitumor immune responses. Moreover, most cancer vaccines require multiple injections to boost the immune responses, leading to poor patient compliance. Controlled-release drug delivery systems are able to address these issues by presenting drugs in a controlled spatiotemporal manner, which allows co-delivery of multiple drugs, reduction of dosing frequency and avoidance of significant systemic toxicities. In this review, we outline the recent progress in cancer vaccines including subunit vaccines, genetic vaccines, dendritic cell-based vaccines, tumor cell-based vaccines and in situ vaccines. Furthermore, we highlight the efforts and challenges of controlled or sustained release drug delivery systems (e.g., microparticles, scaffolds, injectable gels, and microneedles) in ameliorating the safety, effectiveness and operability of cancer vaccines. Finally, we briefly discuss the correlations of vaccine release kinetics and the immune responses to enlighten the rational design of the next-generation platforms for cancer therapy.

show abstract

“…In vitro and in vivo research has produced promising results regarding the application of this vaccination therapy to breast cancer [70]. Chablani et al [71] reported a significant increase in tumor suppression capability after vaccination in murine breast cancer models. The first human studies on the use of personalized RNA mutanome vaccines in combination with PD-1 blockade therapy have been successful for melanoma [72].…”

Section: Vaccine-based Therapiesmentioning

confidence: 99%

Clinical Data on Immunotherapy in Breast Cancer

Radosa¹,

Stotz²,

Müller³

et al. 2020

Breast Care

View full text Add to dashboard Cite

Background: Breast cancer has traditionally been considered to have a low immunogenic potential compared to other tumor entities. Summary: The most extensively studied immunotherapeutic agents for breast cancer to date are immune checkpoint inhibitors, with the results of the IMpassion130 trial leading to the approval of atezolizumab plus nab-paclitaxel for first-line treatment of programmed cell death ligand 1-positive, metastatic, triple-negative breast cancer, and studies in earlier stages have yielded promising results. Other immunotherapeutic options being assessed in phases 2 and 3 trials include vaccine-based therapies and treatment with anti-human epidermal growth factor receptor 2 (H-directed immune-linked antibodies) and substances evaluated in early clinical trials as cellular therapies (adoptive cell therapy and chimeric antigen receptor T cells). Key Messages: Immunotherapy is an emerging modality for the treatment of breast cancer, as evidenced by the plethora of preclinical and clinical concepts and ongoing trials. Early studies established the role of immunotherapeutic agents in the metastatic setting. Ongoing studies will expand our knowledge about the timing of administration, best partners for combination therapy, and predictive biomarkers to guide immunotherapy for breast cancer.

show abstract

Evaluation of a Particulate Breast Cancer Vaccine Delivered via Skin

Cited by 31 publications

References 51 publications

Recent advances in microneedles-mediated transdermal delivery of protein and peptide drugs

Recent advances in microneedles-mediated transdermal delivery of protein and peptide drugs

Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines

Clinical Data on Immunotherapy in Breast Cancer

Contact Info

Product

Resources

About